Dendreon Cutting More Than 600 Jobs in Cost-Saving Move

Dendreon Corp., maker of the prostate cancer drug Provenge, said it would eliminate more than 600 jobs and reduce costs by $150 million during the next 12 months as it seeks to reach profitability.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.